Skip to main content
. 2021 Mar 26;14:50. doi: 10.1186/s13045-021-01063-9

Table 4.

Pralsetinib safety overview

TRAEs with Pralsetinib
(BLU-667), %
ARROW safety population*
(N = 354)
Any Grade ≥ 3
AST 31 2
Anemia 22 8
ALT increased 21 1
Constipation 21 1
Hypertension 20 10
Neutropenia 19 10
Diarrhea 14 1
WBC decreased 14 3
Dysgeusia 13 0
Creatinine increased 13 0
Neutrophil Count Decreased 13 4

*Includes all tumor types (eg, NSCLC, Thyroid, etc.)